Abstract | BACKGROUND: The group-specific component protein-derived macrophage-activating factor ( GcMAF) has various biological activities, such as macrophage activation and antitumor activity. Clinical trials of GcMAF have been carried out for metastatic breast cancer, prostate cancer, and metastatic colorectal cancer. In this study, despite the complicated purification process of GcMAF, we used enzymatically-treated human serum containing GcMAF with a considerable macrophage-stimulating activity and antitumor activity. RESULTS: We detected GcMAF in degalactosylated/desialylated human serum by western blotting using an anti-human Gc globulin antibody, and Helix pomatia agglutinin lectin. We also found that GcMAF-containing human serum significantly enhanced the phagocytic activity of mouse peritoneal macrophages and extended the survival time of mice bearing Ehrlich ascites tumors. CONCLUSION: We demonstrated that GcMAF-containing human serum can be used as a potential macrophage activator for cancer immunotherapy.
|
Authors | Daisuke Kuchiike, Yoshihiro Uto, Hirotaka Mukai, Noriko Ishiyama, Chiaki Abe, Daichi Tanaka, Tomohito Kawai, Kentaro Kubo, Martin Mette, Toshio Inui, Yoshio Endo, Hitoshi Hori |
Journal | Anticancer research
(Anticancer Res)
Vol. 33
Issue 7
Pg. 2881-5
(Jul 2013)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 23780974
(Publication Type: Journal Article)
|
Chemical References |
- Macrophage-Activating Factors
- Sialic Acids
- Vitamin D-Binding Protein
- vitamin D-binding protein-macrophage activating factor
- Galactose
|
Topics |
- Animals
- Blotting, Western
- Carcinoma, Ehrlich Tumor
(metabolism, pathology, prevention & control)
- Female
- Galactose
(metabolism)
- Humans
- Macrophage Activation
(drug effects)
- Macrophage-Activating Factors
(pharmacology)
- Macrophages, Peritoneal
(cytology, drug effects, metabolism)
- Mice
- Mice, Inbred ICR
- Phagocytosis
(drug effects)
- Serum
(chemistry)
- Sialic Acids
(metabolism)
- Vitamin D-Binding Protein
(pharmacology)
|